Carolyn Wallace

Carolyn Wallace is an accomplished finance professional with extensive experience in business development within the biotechnology industry. Currently serving as Head of Business Development Finance at Genentech since July 2013, Carolyn has successfully negotiated financial provisions for over 50 in-licensing opportunities worth more than $2 billion. Carolyn's expertise includes developing deal structures for collaborations across various therapeutic stages, acting as a senior financial reviewer for complex agreements, and leading significant transactions, such as supporting a ~$1 billion acquisition of a breast cancer drug company. Prior roles at Amgen involved leadership in clinical drug manufacturing campaigns, focusing on research and development in small molecules, while earlier experience at GE included technical sales and product development. Carolyn's academic credentials comprise an MBA in Health Sector Management and Finance from Duke University and a BS in Chemical Engineering from Cornell University.